Search research articles
Contact Us
Filters
Showing results (261-270 of 278) with videos related to
Page
of 28
Sort By:
Blood
|
April 18, 2024
Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity
Frederick L Locke, Tanya Siddiqi, Caron A Jacobson, et al.
Transplantation and Cellular Therapy
|
June 27, 2026
Infections within 100 days of idecabtagene vicleucel and impact on survival for relapsed/refractory multiple myeloma: A CIBMTR Analysis
Kitsada Wudhikarn, Lohith Gowda, Qiran Ye, et al.
American Journal of Hematology
|
October 11, 2025
Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response
Rahul Banerjee, Gurbakhash Kaur, Beatrice M Razzo, et al.
Blood Advances
|
July 30, 2025
Real-World Outcomes of Infections Following Tisagenlecleucel in Patients with B-Cell ALL: A CIBMTR Analysis
Hemalatha G Rangarajan, Prakash Satwani, Megan M Herr, et al.
Blood Advances
|
November 7, 2025
Outcomes for CART as 2L vs 3L vs 4L or Beyond in Aggressive B-cell Lymphoma: Real World Evidence from the ABC Consortium
John Seng Wang, Brandon Lee Ellsworth, Megan Melody, et al.
Blood Advances
|
August 28, 2025
Safety and Efficacy of BCMA directed Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Plasma Cell Leukemia
Gliceida M Galarza Fortuna, Lauren C Peres, Elena Nazarenko, et al.
Blood Advances
|
May 28, 2025
Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR
Kitsada Wudhikarn, Megan M Herr, Min Chen, et al.
Blood Cancer Journal
|
March 28, 2026
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium
Andrew J Portuguese, James A Davis, Shahzad Raza, et al.
Blood Cancer Journal
|
June 25, 2025
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
Danai Dima, Mariola A Vazquez-Martinez, James A Davis, et al.
Blood Advances
|
April 8, 2025
Teclistamab for Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma and Renal Impairment
Danai Dima, Aimaz Afrough, Utkarsh Goel, et al.
Page
of 28
Search research articles
Search
Showing results (261-270 of 278) with videos related to
Sort By:
Page
of 28
Blood
|
April 18, 2024
Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity
Frederick L Locke, Tanya Siddiqi, Caron A Jacobson, et al.
Transplantation and Cellular Therapy
|
June 27, 2026
Infections within 100 days of idecabtagene vicleucel and impact on survival for relapsed/refractory multiple myeloma: A CIBMTR Analysis
Kitsada Wudhikarn, Lohith Gowda, Qiran Ye, et al.
American Journal of Hematology
|
October 11, 2025
Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response
Rahul Banerjee, Gurbakhash Kaur, Beatrice M Razzo, et al.
Blood Advances
|
July 30, 2025
Real-World Outcomes of Infections Following Tisagenlecleucel in Patients with B-Cell ALL: A CIBMTR Analysis
Hemalatha G Rangarajan, Prakash Satwani, Megan M Herr, et al.
Blood Advances
|
November 7, 2025
Outcomes for CART as 2L vs 3L vs 4L or Beyond in Aggressive B-cell Lymphoma: Real World Evidence from the ABC Consortium
John Seng Wang, Brandon Lee Ellsworth, Megan Melody, et al.
Blood Advances
|
August 28, 2025
Safety and Efficacy of BCMA directed Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Plasma Cell Leukemia
Gliceida M Galarza Fortuna, Lauren C Peres, Elena Nazarenko, et al.
Blood Advances
|
May 28, 2025
Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR
Kitsada Wudhikarn, Megan M Herr, Min Chen, et al.
Blood Cancer Journal
|
March 28, 2026
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium
Andrew J Portuguese, James A Davis, Shahzad Raza, et al.
Blood Cancer Journal
|
June 25, 2025
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
Danai Dima, Mariola A Vazquez-Martinez, James A Davis, et al.
Blood Advances
|
April 8, 2025
Teclistamab for Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma and Renal Impairment
Danai Dima, Aimaz Afrough, Utkarsh Goel, et al.
Page
of 28